| | 
Part, Chapter, Paragraph
1 II, 4. 3 | Executive summary. Washington, DC, U.S. Department of Health
2 II, 5. 3. 9| Perspective. Washington DC: AICR.~ ~WHO (2003): Strategies
3 II, 5. 5. 3| 231.~Brewis M, Poskanzer DC, Rolland C, Miller H (1966):
4 II, 5. 6. 6| the World Bank, Washington DC~Magaziner J, Simonsick EM,
5 II, 5. 7. 7| K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, et
6 II, 5. 12. 7| Ioannou G, Doust J, Rockey DC (2003): Terlipressin for
7 II, 8. 2. 1| Supports (10th Ed) Washington, DC: American Association on
8 II, 8. 2. 1| 4th Edition, Washington DC, American Psychiatric Association.~
9 III, 10. 5. 1| Urban Audit (htt ~ ~Tranter DC (2005): Indoor allergens
10 III, 10. 6. 1| 167(18):1951-7.~ ~Ganster DC, Victor B (1998). The impact
11 IV, 11. 6. 5| Care Costs? Washington, DC, Government Printing Office.~ ~
|
|
| |